Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype

Matthew D. Hill(Arkansas State University), Andrew P. Degnan(Bristol-Myers Squibb (United States)), Claude Quesnelle(Bristol-Myers Squibb (United States)), Carolynn Fanslau(Bristol-Myers Squibb (United States)), Melissa Kramer(Bristol-Myers Squibb (United States)), Shilpa Madari(Bristol-Myers Squibb (United States)), Chunshan Xie(Bristol-Myers Squibb (United States)), John S. Tokarski(Bristol-Myers Squibb (Germany)), Tatyana Zvyaga(Bristol-Myers Squibb (Germany)), Jean Simmermacher-Mayer(Bristol-Myers Squibb (United States)), Francis Lee(Bristol-Myers Squibb (United States)), Haiquan Fang(Bristol-Myers Squibb (United States)), Zuzana Haarhoff(Bristol-Myers Squibb (United States)), S. Sheriff(Bristol-Myers Squibb (United States)), Richard A. Westhouse(Bristol-Myers Squibb (United States)), Lisa Huang(Bristol-Myers Squibb (United States)), Gerry Everlof(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Amy E. Wiebesiek(Bristol-Myers Squibb (United States)), Chunhong Yan(Bristol-Myers Squibb (United States)), Jiuqiao Zhao(Bristol-Myers Squibb (United States)), Frank Marsilio(Bristol-Myers Squibb (United States)), J. S. Morrison(Bristol-Myers Squibb (United States)), Ashvinikumar V. Gavai(Bristol-Myers Squibb (United States))

Bioorganic & Medicinal Chemistry Letters

September 21, 2021

Cited by 6

|Drug Metabolism and Disposition|2002|447

|Journal of the American Chemical Society|2007|380

|Chemical Research in Toxicology|1998|312

|Journal of the American Chemical Society|2006|279

|Journal of the American Chemical Society|2006|255

Related Papers